Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoBio Corporation Raises $12 Million in Series B Financing

Abstract:
NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, announced today that it has acquired $12 million in series B equity financing with Perseus LLC and other existing investors. To date, over $80 million in funding has been directed toward the development of the company's NanoStat(TM) technology platform.

NanoBio Corporation Raises $12 Million in Series B Financing

Ann Arbor, MI | Posted on February 18th, 2009

The series B funding will be used by the company to complete a phase 1 study investigating a novel topical treatment for acne, preclinical studies on a nebulized therapy for cystic fibrosis, and a phase 1 study for an intranasal seasonal influenza vaccine.

This funding follows several recent product announcements by NanoBio, including:

-- Phase 2b data indicating that the company's topical herpes labialis product speeds healing as effectively as the leading oral systemic drugs but without safety or toxicity concerns

-- Preclinical data demonstrating that the company's novel nanoemulsion technology kills highly resistant bacteria found in patients with cystic fibrosis

-- Preclinical data indicating that a single administration of NanoBio's novel intranasal influenza vaccine elicits immune responses in ferrets more than 20 times higher than those generated by two injections of currently approved vaccines

"We are pleased with the continued, strong support of Perseus and the company's other investors," said James R. Baker Jr., M.D., founder and chairman of NanoBio Corp. "Based upon the strength of our recent data and our future development plans, there was significant interest from investors with respect to participating in this financing despite the challenging economic conditions."

####

About NanoBio Corp.
NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.

For more information, please click here

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Silver nanoparticles are toxic for aquatic organisms: A research team at the UPV/EHU-University of the Basque Country has analysed how zebrafish are affected in the long term by exposure to silver particles September 19th, 2018

Leti Announces EU Project to Develop Powerful, Inexpensive Sensors with Photonic Integrated Circuits: REDFINCH Members Initially Targeting Applications for Gas Detection and Analysis For Refineries & Petrochemical Industry and Protein Analysis for Dairy Industry September 19th, 2018

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. to Provide Live Remote Access to Its Annual Meeting of Shareholders on June 12, 2018 June 12th, 2018

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Nanowire LED Innovator Aledia Announces 30 ($36M) Million Series-C Financing: Intel Capital Joins Existing Investors to Commercialize Certain Nanowire-LED Technologies for Mobile Displays January 29th, 2018

180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017

Announcements

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Silver nanoparticles are toxic for aquatic organisms: A research team at the UPV/EHU-University of the Basque Country has analysed how zebrafish are affected in the long term by exposure to silver particles September 19th, 2018

Leti Announces EU Project to Develop Powerful, Inexpensive Sensors with Photonic Integrated Circuits: REDFINCH Members Initially Targeting Applications for Gas Detection and Analysis For Refineries & Petrochemical Industry and Protein Analysis for Dairy Industry September 19th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project